AKY-1189 Investigational Nectin-4-targeting miniprotein radioconjugate delivering actinium-225 to solid tumors; currently in Phase 1b clinical development.
Visit productCosigns Received
Be the first Cosign
Put your name behind AKY-1189.
Add it to your Products I use list and share why you use it.